CCR5 Recombinant Rabbit Monoclonal Antibody (2H14L10), Invitrogen™

Descripción

This antibody is predicted to react with Monkey Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.

Human immunodeficiency virus (HIV) and related virus require coreceptors, in addition to CD4, to infect target cells. Some G protein-coupled receptors including CCR5, CXCR4, CCR3, CCR2b and CCR8 in the chemokine receptor family, and four new human molecules GPR15, STRL33, GPR1 and V28 were recently identified as HIV coreceptors. Among them, CCR5 (CC-CKR-5) is a principal coreceptor for macrophage- and dual-tropic HIV-1 strains fusion and entry of human white blood cells. CCR5 is required for the infection by HIV-1, HIV-2, and SIV. The beta-chemokines RANTES, MIP-alpha and MIP-beta are the ligands for CCR5 and prevent infection by M-tropic HIV-1. CCR5 associates with the surface CD4-gp120 of HIV complex and leads to membrane fusion and virus entry of target cells. The amino-terminal domain and the extracellular loops of CCR5 serve as HIV biding sites. CCR5 messenger RNA is expressed in lymphoid organs and monocytes.